<SEC-DOCUMENT>0001571049-16-011529.txt : 20160205
<SEC-HEADER>0001571049-16-011529.hdr.sgml : 20160205
<ACCEPTANCE-DATETIME>20160205163053
ACCESSION NUMBER:		0001571049-16-011529
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20160202
ITEM INFORMATION:		Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160205
DATE AS OF CHANGE:		20160205

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		161392643

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>t1600342_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 18pt"><B>FORM 8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Pursuant
to Section 13 or 15(d)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>of the
Securities Exchange Act of 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 12pt"><B>Date
of Report (Date of earliest event reported): February 2, 2016</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 24pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CYCLACEL PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Exact name of registrant as specified
in its charter)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>0-50626</B></FONT></TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>91-1707622</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>(State
    or other jurisdiction</B></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>(Commission
    File Number)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>(IRS
    Employer</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>of
    incorporation)</B></FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Identification
    No.)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>200 Connell Drive, Suite 1500</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Berkeley Heights, NJ 07922</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Address
of principal executive offices and zip code)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Registrant&rsquo;s telephone number,
including area code: (908) 517-7330</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>(Former
Name or Former Address, if Changed Since Last Report)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing</B> <B>obligation of the registrant under any of the following provisions ( <I>see
</I>General Instruction A.2. below):</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))</B></FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Wingdings">&uml;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 3.01 Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As previously disclosed, on February 2,
2015, Cyclacel Pharmaceuticals, Inc., a Delaware corporation (the &ldquo;Company&rdquo;) received notice from the Listing Qualifications
Staff (the &ldquo;Staff&rdquo;) of The NASDAQ Stock Market LLC (&ldquo;NASDAQ&rdquo;) indicating that, based upon the closing bid
price of the Company&rsquo;s common stock (the &quot;Common Stock&quot;) for the previous 30 consecutive business days, the Company
no longer satisfied the requirement to maintain a minimum bid price of $1.00 per share, as required by NASDAQ Listing Rule 5450(a)(1)
(the &quot;Bid Price Rule&quot;). In accordance with the NASDAQ Listing Rules, the Company was afforded 180 days, or until August
3, 2015, to regain compliance with the Bid Price Rule by evidence of a closing bid price of at least $1.00 per share for a minimum
of 10 consecutive business days. In anticipation of not meeting the Bid Price Rule by August 3, 2015, the Company transferred the
listing of its Common Stock to the NASDAQ Capital Market, upon which it was afforded an additional 180 calendar days, or until
February 2, 2016, to regain compliance with the Bid Price Rule by evidence of a closing bid price of at least $1.00 per share for
a minimum of 10 consecutive business days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company was unable to regain compliance
with the Bid Price Rule by February 2, 2016. Accordingly, on February 2, 2016, the Company received a letter from the Staff notifying
it that its Common Stock would be subject to delisting from NASDAQ unless the Company timely requested a hearing before a NASDAQ
Listing Qualifications Panel (the &quot;Panel&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company intends to timely request a
hearing before the Panel, at which it will present its plan to evidence compliance with the Bid Price Rule, and request a further
extension of time to do so. The Panel has the discretion to grant the Company up to an additional 180 calendar days from the date
of the Staff&rsquo;s notice, or until August 1, 2016, to satisfy the Bid Price Rule. The Company&rsquo;s request for a hearing
will automatically stay any delisting action pending the issuance of a final decision and the expiration of any further extension
granted by the Panel. There can be no assurance that the Panel will grant the Company&rsquo;s request for continued listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On February 5, 2016, the Company issued
a press release, a copy of which is filed herewith as Exhibit 99.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.55pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B>(d) Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; width: 10%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font-weight: bold; padding-bottom: 2px; width: 2%"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; width: 88%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release issued on February 5, 2016.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>
<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CYCLACEL PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid; width: 44%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul McBarron</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Vice President&mdash;Finance,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Chief Operating Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: left; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: February 5, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>t1600342_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <TD STYLE="vertical-align: top; width: 50%; font-size: 10pt"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1logo.jpg" ALT=""></font></td>
    <TD STYLE="width: 50%; font-size: 10pt; text-align: right"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cyclacel Pharmaceuticals, Inc.</font></td></tr>
</table>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="pg1.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Cyclacel
Announces Receipt of NASDAQ Staff Determination;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Company
to Request Hearing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BERKELEY HEIGHTS, N.J., February 5, 2016 &mdash; Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC; CYCCP) (&ldquo;Cyclacel&rdquo; or the &ldquo;Company&rdquo;)
today announced that on February 2, 2016, the Company received a letter from the Listing Qualifications Staff (the &ldquo;Staff&rdquo;)
of The NASDAQ Stock Market LLC (&ldquo;NASDAQ&rdquo;) indicating that the Company had not regained compliance with the $1.00 minimum
bid price requirement for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Listing Rule 5450(a)(1), by the
end of the previously granted compliance period that expired on February 2, 2016. As a result, the Staff indicated that the Company
would be subject to delisting unless it timely requests a hearing before a NASDAQ Listing Qualifications Panel (the &quot;Panel&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company intends to timely request a
hearing before the Panel, at which it will present its plan to regain compliance with the minimum bid price requirement, and request
a further extension of time to do so. The Panel has the discretion to grant the Company up to an additional 180 calendar days from
the date of the Staff&rsquo;s notice, or until August 1, 2016, to regain compliance with the minimum bid price requirement. The
request for a hearing will automatically stay any delisting action pending the issuance of a final decision and the expiration
of any further extension granted by the Panel. There can be no assurance that the Panel will grant the Company&rsquo;s request
for continued listing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Cyclacel is a
biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of
cancer and other serious diseases. Sapacitabine, Cyclacel's most advanced product candidate, is the subject of SEAMLESS, a Phase
3 trial, which has completed enrollment and is being conducted under an SPA with the FDA as front-line treatment for acute myeloid
leukemia (AML) in the elderly, and other indications including myelodysplastic syndromes (MDS). Cyclacel's pipeline includes an
oral regimen of seliciclib in combination with sapacitabine in a Phase 1 study of patients with Homologous Recombination (HR)
repair-deficient breast, ovarian and pancreatic cancers, including BRCA positive tumors, and CYC065, a novel CDK2/9 inhibitor
in a Phase 1 study of patients with solid tumors with potential utility in both hematological malignancies and solid tumors. Cyclacel's
strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline
of novel drug candidates. Please visit <U>www.cyclacel.com</U> for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 8pt">&thorn;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">200 Connell Drive, Suite 1500, Berkeley Heights,
New Jersey 07922, USA Tel +1 (908) 517 7330 Fax +1 866 271 3466</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Wingdings; font-size: 8pt">&uml;
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 8pt">Dundee Technopole, James Lindsay Place, Dundee,
DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt"><U>www.cyclacel.com
</U>&ndash; <U>info@cyclacel.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This news release contains certain forward-looking statements
that involve risks and uncertainties that could cause actual results to be materially different from historical results or from
any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety
and intended utilization of Cyclacel's product candidates, the conduct and results of future clinical trials, plans regarding regulatory
filings, future research and clinical trials and plans regarding partnering activities. Factors that may cause actual results to
differ materially include the risk that product candidates that appeared promising in early research and clinical trials do not
demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may
not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements,
and the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization
of product candidates. You are urged to consider statements that include the words &quot;may,&quot; &quot;will,&quot; &quot;would,&quot;
&quot;could,&quot; &quot;should,&quot; &quot;believes,&quot; &quot;estimates,&quot; &quot;projects,&quot; &quot;potential,&quot;
&quot;expects,&quot; &quot;plans,&quot; &quot;anticipates,&quot; &quot;intends,&quot; &quot;continues,&quot; &quot;forecast,&quot;
&quot;designed,&quot; &quot;goal,&quot; or the negative of those words or other comparable words to be uncertain and forward-looking.
For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report
on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov.
Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking
statements, whether as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Contacts for Cyclacel Pharmaceuticals, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Company: Paul McBarron, (908) 517-7330, <U>pmcbarron@cyclacel.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Investor Relations/Media: Russo Partners LLC, Robert Flamm,
(212) 845-4226, <U>robert.flamm@russopartnersllc.com</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&copy; Copyright 2016 Cyclacel Pharmaceuticals,
Inc. All Rights Reserved. CYC065, sapacitabine and seliciclib are investigational agents not approved for human use by any regulatory
agency. The Cyclacel logo and Cyclacel<SUP>&reg;</SUP> are trademarks of Cyclacel Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1logo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 1 "U P$1  (1 0,1 ?_$ *D  0 " P$! 0$
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M8/[>=MN*1CXY3*GK3U"%+3J+BP.GZ:*2I -M3LA*?&QK[]J(N9R9D#&7B9U
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MV.(MHY;R;P$TU55C) "OQ_85XTWKOK<O(.7&;W0^'YJ6DMILE*$(0DDA*4)
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M[/.S4."W[AO()G=?&]%F5@)\^)C[Y>7M)@4&SP2$<(-&+=65=)&1[BAVMS%
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M3(4KQ_7LJ1#$PIF$$U!+:G:0(]0$0.)!#\73E7<DHM<E\DQU7]6_AI(1IO\
M"ER(M77R^2#J_"_E7QM*(F1P]Q!-1;T+&X8:G-1  4MJ>A/3S^>I(3YW*?.I
M,MZRT6R%=C2C=,4O^XQ3K!91?$[ 6;-\!5(V.52G%(#JH(6TT-\43#V?*)V%
M,/3M&!+GN)PD01U'5^QWFVM)O8G(O>I%K]"6>_KMUTFY'G6S6\6RO<<XRTC1
M_)49Y_6+7 Q,?T9O:Y D>FT7Z:Q8'RJRWFAZZ?K5.3\.4[,S%>KY-:(W3&,M
M R$):\16.(K<UC^Z*+S-<G(B7LC&4A'<NO(U=[70%B5!X@UZNE3+(K*%0.BI
M6U@     .@!Z  >@  ?T  XI3BE1YVZR#8L2ZH;/94J"J2%LQGKSFG(-777(
M91%&Q4S&UEL<*JLF4Q3*))R4:D)@ 0$0#IUXI50/\9G"F.\>>)O ^6Z^=A8\
MH[1.[UG#/&352H/+9>\BS60;9'+I6F>%1Q(2;FILX\D<!%E1]M=)=3L(JNMW
M*5?!<:?5\A5*T4.[P,9::9=:_,52V5J9:IO8BP5NPQ[B)FX64:*@*;EA)QKM
M1%8@^ADSB'%*X:9.F[MZY7V^_P 7O$<C8QQELA?BY%U]VM=SGO3.'?&G?%;)
M9M@J4Y355!T]M]=F(5_76':4B3HTB] ?:3<,^Q2IW>:K!6+J4CX(_%)56S''
M^EN5=Q*?1,@TLCEP@TMM(PDUI9JU0+$Y25;)S"5ZE;@X4>G< 95W-&0=B/O%
M$PJ5U<0<'"UF%B:Y6XB,@*] 1K*&@X*%8M8N'AHB,;)LXZ+BXUDD@SCXY@T1
M(DBBD0B:290*4   #BE<XGEF_P#V@_CT_P#5W;C_ -JJEQ2ND_BE<K%#KF(/
M*AY=/(ME'-$]4I'5[3S UI\8.(XJ:G81HC,9+RQ$2([5W>&0>N?<)*P+:2<U
MTCXG:15LX1,D(F2,8%*W1X#-A[=5-'=C=+\@OTKIGOQ2Y,RWKZ[:(/$7;J\X
MRK1IZSX(LT>JQ<2)%82Q0*"T1'F2$_1O%D#MZB'<I6*_Q7:=7K/X^+7N38F@
M3FR>XFQF=[_GW)4R8C^WV"6A,CSM?A8!W**E%\A!Q#9F=V@R$033<R"Z@% %
M"@"E7\;._P#UKV%_Z'99_P#(4_Q2N/GP8^0S?G"/BVU>QGA_PZ[ ;.XYKD?D
M@M8SA3LYXGJ%9O"$AER^2CY:+K]F9J3+ D/+/'$>I[HB!UFASE_"8.*5.'S
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GO"OKY3JM3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>pg1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pg1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ & ). P$1  (1 0,1 ?_$ &\  0 " @,! 0
M       '" 8) P0% 0H! 0                     0   & @ & @$$ 04!
M 0    $" P0%!@ '$1)6EM88$P@A,4$B%111,D(S%B,7$0$
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<*OV<80Y"*UXAW!A>/TB\B8'. &$PARE,8 __V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
